Kura Oncology to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two investor conferences in March 2022. He will join a panel on "Leukemias/MPN" at the Cowen 42nd Annual Health Care Conference on March 7 at 10:30 a.m. ET, followed by a fireside chat at the Barclays Global Healthcare Conference in Miami on March 15 at 11:15 a.m. ET. Audio webcasts of both events will be available on Kura's website, with replays archived post-event. Kura focuses on precision cancer medicines and has notable candidates like Ziftomenib and Tipifarnib in clinical trials.

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences:

• A “Leukemias/MPN” panel discussion at the virtual Cowen 42nd Annual Health Care Conference at 10:30 a.m. ET / 7:30 a.m. PT on March 7, 2022; and
  
  
• A podium/fireside chat at the Barclays Global Healthcare Conference in Miami at 11:15 a.m. ET / 8:15 a.m. PT on March 15, 2022.
  

Audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company is also developing KO-2806, a next-generation FTI, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

What investor conferences is Kura Oncology participating in March 2022?

Kura Oncology will participate in the Cowen 42nd Annual Health Care Conference on March 7 and the Barclays Global Healthcare Conference on March 15, 2022.

What time is the Cowen 42nd Annual Health Care Conference panel discussion?

The Cowen 42nd Annual Health Care Conference panel discussion is scheduled for 10:30 a.m. ET on March 7, 2022.

When will Kura's fireside chat at the Barclays Global Healthcare Conference take place?

Kura's fireside chat at the Barclays Global Healthcare Conference is set for 11:15 a.m. ET on March 15, 2022.

Where can I watch Kura Oncology's investor conference webcasts?

Audio webcasts of Kura Oncology's investor conferences will be available on their website in the Investors section.

What are the main focuses of Kura Oncology's drug development pipeline?

Kura Oncology focuses on precision medicines for cancer treatment, with candidates like Ziftomenib and Tipifarnib targeting specific cancer pathways.